

## **SUPPLEMENTARY INFORMATION**

### **INTEGRATIVE miRNA AND GENE EXPRESSION PROFILING ANALYSIS OF HUMAN QUIESCENT HEPATIC STELLATE CELLS**

Mar Coll<sup>1\*</sup>, Adil El Taghdouini<sup>2\*</sup>, Luis Perea<sup>1</sup>, Inge Mannaerts<sup>2</sup>, Maria Vila-Casadesús<sup>3</sup>, Delia Blaya<sup>1</sup>, Daniel Rodrigo-Torres<sup>1</sup>, Silvia Affò<sup>1</sup>, Oriol Morales-Ibanez<sup>1</sup>, Isabel Graupera, Juan José Lozano<sup>3</sup>, Mustapha Najimi<sup>4</sup>, Etienne Sokal<sup>4</sup>, Joeri Lambrecht<sup>2</sup>, Pere Ginès<sup>1,3,5</sup>, Leo A. van Grunsven<sup>2</sup> and Pau Sancho-Bru<sup>1,3\*</sup>.

*\*equal contribution*

<sup>1</sup> Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.

<sup>2</sup> Liver Cell Biology Lab, Faculty of Medicine and Pharmacy, Vrije Universiteit Brussel (VUB), Brussels, Belgium.

<sup>3</sup> Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Barcelona, Spain.

<sup>4</sup> Laboratory of Pediatric Hepatology and Cell Therapy, Institute of Experimental & Clinical Research, Université Catholique de Louvain, Brussels, Belgium.

<sup>5</sup> Liver Unit, Hospital Clínic, Faculty of Medicine, University of Barcelona, Barcelona, Spain.

**Supplementary Table 1.**Clinical characteristics of cadaveric liver donors

<b>liver ID</b>	<b>isolated cells</b>	<b>age</b>	<b>gender</b>	<b>ischemia time</b>	<b>Cause of brain death</b>
L4	qHSC and LSEC	12 years	female	16h30	Drowned
L8	qHSC and LSEC	1 days	male	4h40	Sudden death of unknown cause
L10	qHSC and LSEC	7 months	female	5h20	Sudden death of unknown cause
L11	qHSC and LSEC	7 days	male	4h25	Sudden death of unknown cause
F3	Hepatocytes	17 years	male	9h	Trauma
F23	Hepatocytes	16 years	female	<10h	Trauma

**Supplementary Table 2.** Characteristics of patients with cirrhosis and alcoholic hepatitis

Validation Cohort (n=15)	
Characteristics	Median (25-75 IQR)
Age (y)	54 (49-60)
Male n (%)	87
Alcohol intake (g/day)	100 (90-200)
<b>Laboratory and hemodynamic parameters</b>	
Hemoglobin (g/dL)	11.8 (10.7-13.5)
Leukocyte count $\times 10^9$ /L	7.64 (4.3-11)
Platelet count $\times 10^9$ /L	124 (84-208)
AST (U/L)	127 (104-240)
ALT (U/L)	58 (14-67)
Serum albumin (g/dL)	29 (24-32.5)
Serum creatinine (mg/dL)	0.9 (0.6-1.3)
Serum bilirubin (mg/dL)	10 (1.7-19.6)
International normalized ratio	1.4 (1.2-1.8)
HVPG (mmHg)	17 (10-22)
<b>Alcoholic hepatitis severity</b>	
MELD score	21 (11-24)
ABIC score	7.9 (6.8-8.8)
Maddrey score	68.3 (62.8-82.5)

IQR, interquartile range; AST, aspartate aminotransferase level;  
ALT, alanine aminotransferase level; HVPG, hepatic venous  
pressure gradient; MELD, model for end-stage liver disease;  
ABIC, age-bilirubin-INR-creatinine score.

**Supplementary Table 3.**List of primers used for gene expression analysis

Gene Name	Forward sequence	Reverse sequence
<b>GAPDH</b>	AGCCACATCGCTCAGACAC	GCCCAATACGACCAAATCC
<b>ALBUMIN</b>	TGGCACAAATGAAGTGGTAA	CTGAGCAAAGGCAATCAACA
<b>PDGFR<math>\beta</math></b>	CCCTTATCATCCTCATCATGC	CCTTCCATCGGATCTGTAA
<b>CD32b</b>	AGTCCCAGCATGGGCAGC	TGTCTCTTCTGATGGCAAT
<b>F4/80</b>	GCCAGTTGCACAGTTAGTGA	GACTTCGGCATTAAACACTGGA
<b>ACTA2</b>	CTGTTCCAGGCCATCCTTCAT	TCATGATGCTGTTGTAGGTGG
<b>COL1A1</b>	GACACAGAGGTTTCAGTGG	CACCCTTAGCACCAACAG
<b>LOX</b>	CACAGTTGTCAACATTAC	CTGACCTTTAGGATATAAGTCCAG
<b>SPARCL1</b>	GGATTCAACTTCAATTTCCTGC	AGAAGGTTGGTGGATTACTTGA
<b>ATP1B2</b>	GAGGACGCACCAGTTATGG	AACATGGCGGTGAGGAAC
<b>BTG2</b>	AGCGAGCAGAGGCTTAAGGT	CGGTAGGACACCTCATAGGG
<b>SPRY1</b>	GTGTGTTGGAAATCCACG GT	AAAGAAGGCTGCTGGATCAC
<b>PLAU</b>	TCACCACAAACGACATTGCCT	TGATCTCACAGCTTGCCAAA
<b>COL5A1</b>	CACAACTTGCCTGATGGAATAACA	GCAGGGTACAGCTGCTTGGT
miRNA	primer sequence	
<b>hsa-miR-192</b>	CTGACCTATGAATTGACAGCC	
<b>mmu-miR-192</b>	CTGACCTATGAATTGACAGCC	
<b>hsa-miR-139-5p</b>	TCTACAGTGCACGTGTCCTCAGT	
<b>hsa-miR-139-3p</b>	TGGAGACGCGGCCCTGTTGGAGT	
<b>hsa-miR-485-5p</b>	AAGACGGGAGGAAAGAAGGGAG	
<b>hsa-miR-142-3p</b>	TGTAGTGTTCCTACTTTATGGA	
<b>hsa-miR-375</b>	TTTGTTCGTTGGCTCGCGTGA	
<b>hsa-miR-100</b>	AACCGTAGATCCGAACTTGTG	
<b>hsa-miR-125b-1*</b>	ACGGGTTAGGCTTGGGAGCT	
<b>hsa-miR-132</b>	TAACAGTCTACAGCCATGGTCG	
<b>hsa-miR-21</b>	UAGCUUAUCAGACUGAUGUUGA	

**Supplementary Table 4.** Up-regulated miRNAs in human culture-activated compared to quiescent HSCs.

miRNA	FC (Q vs. A)	P value	Target genes
<b>miR-100</b>	112,49	$6 \cdot 10^{-7}$	CPNE5, BTG2, SPARCL1, PPAP2A, ABCG2
<b>miR-99a</b>	74,36	$1 \cdot 10^{-6}$	CPNE5, BTG2
<b>miR-130b</b>	11,38	$6,3 \cdot 10^{-5}$	ITGB4, ENTPD1
<b>miR-625</b>	7,93	0,0003	C7
<b>miR-29a</b>	68,21	0,0003	none
<b>miR-222</b>	37,30	0,0003	none
<b>miR-28</b>	6,39	0,0003	none
<b>miR-365</b>	8,56	0,0005	ST8SIA6, NR4A2, RASD1
<b>miR-576-3p</b>	15,96	0,0006	none
<b>miR-106b</b>	6,52	0,0006	ST8SIA6
<b>miR-143</b>	46,64	0,0006	TESC, ENTPD1
<b>miR-22</b>	30,56	0,0006	C7
<b>miR-19b</b>	4,58	0,0006	ITM2A
<b>miR-224</b>	16,59	0,0007	none
<b>miR-125b</b>	22,62	0,0007	none
<b>miR-24</b>	9,89	0,0007	none
<b>miR-222*</b>	134,47	0,0008	COL9A3
<b>miR-362</b>	14,83	0,0009	none
<b>miR-374</b>	7,52	0,0009	none
<b>miR-517b</b>	47,23	0,0010	LTBP4
<b>miR-10b</b>	10,13	0,0010	TESC, ITM2A
<b>miR-34a*</b>	42,93	0,0010	CCL19, SPP1
<b>miR-27b</b>	26,92	0,0011	SPARCL1
<b>miR-130a</b>	10,49	0,0011	none
<b>miR-376a</b>	28,77	0,0011	PPAP2A
<b>miR-27a</b>	34,84	0,0012	CCL19, SPARCL1
<b>miR-589</b>	9,28	0,0012	none
<b>miR-193a-3p</b>	237,84	0,0013	none
<b>miR-210</b>	99,97	0,0014	COL9A3
<b>miR-34c</b>	15,94	0,0014	none

**Supplementary Table 5.**Differentially expressed genes found targeted by a high number of deregulated miRNAs

mRNAs	FC.mRNA (Q vs. A)	miRNAs
ENTPD1	5,62	miR-130b, miR-143, miR-23a, miR-27b*, miR-335*, miR-337-5p, miR-539, miR-654-3p, miR-708, miR-758
SPARCL1	55,47	miR-100, miR-140-3p, miR-152, miR-154*, miR-199a-3p, miR-19b-1*, miR-27a, miR-27b, miR-301b, miR-655
VCAM1	13,98	miR-132, miR-181a, miR-22*, miR-340, miR-376c, miR-424, miR-487a, miR-671-3p, miR-935
ST8SIA6	14,01	let-7i*, miR-106b, miR-184, miR-31, miR-31*, miR-365, miR-616, miR-98
MTHFD1L	-9,43	miR-126*, miR-142-5p, miR-200a, miR-429, miR-522, miR-605, miR-638
PFKP	-16,73	miR-139-3p, miR-139-5p, miR-142-5p, miR-372, miR-523, miR-548b-5p, miR-628-5p
ACOT7	-4,97	miR-139-3p, miR-200a, miR-200b, miR-302c*, miR-375, miR-429
COL9A3	4,08	let-7b*, miR-210, miR-222*, miR-31*, miR-597, miR-598
DCBLD1	-4,11	miR-126, miR-139-3p, miR-302c*, miR-342-5p, miR-363, miR-885-5p
ITM2A	10,63	let-7a*, let-7b*, let-7i*, miR-10b, miR-19a, miR-19b
LOX	-67,33	miR-126*, miR-200a, miR-200b, miR-429, miR-548b-5p, miR-628-5p
PPAP2A	2,86	let-7g, miR-100, miR-181a-2*, miR-18b, miR-376a, miR-503
BTG2	23,21	miR-100, miR-18b, miR-21, miR-31, miR-99a
CCL19	5,52	miR-27a, miR-339-5p, miR-345, miR-34a*, miR-671-3p
DOCK7	-8,94	miR-126*, miR-135a, miR-142-5p, miR-223, miR-522
FAP	-26,34	miR-126, miR-135a, miR-200a, miR-375, miR-429
SPP1	21,36	miR-130b*, miR-181a, miR-34a*, miR-376c, miR-424
TESC	4,79	miR-10a, miR-10b, miR-143, miR-339-5p, miR-532-3p
WNK4	-7,06	miR-135a, miR-142-3p, miR-202, miR-342-5p, miR-639


## **FIGURE LEGENDS**

**Supplementary Figure 1: Integrative analysis pipeline:** **(A)** Differential microRNA and mRNA expression analysis. Heatmaps represent the 50 most significant miRNAs and mRNAs together with the volcano plots of the differential expressed miRNAs and mRNAs. Red and black dots represent significant ( $FDR < 0.05$ ) and non-significant differential expressed genes/miRNAs, respectively **(B)** Correlation and intersection with Microcosm Database. The table shows the basic statistics for correlations between miRNA and target genes. Only those miRNA-mRNA pairs with Pearson Correlation Coefficient  $< 0$  and  $FDR < 0.05$  were considered and used for the intersection with Microcosm Database (8.7% of all potential correlations). Among all miRNA-target pairs predicted by MicroCosm (8463) only 9.16% present a negative and significant correlation and were considered for further analysis.

**Supplementary Figure 2: *In vitro* modulation of miRNA expression in human HSCs (LX2).** Reduction of miR-21 and miR-100 expression and up-regulation of miR-192 in LX2 cells was achieved by transfecting miR-21 antagonir (50nM), miR-100 antagonir (50nM) or miR-192 mimic (50nM), respectively (n=2) or control mimic/inhibitor. All expressions are relative to the solvent (blank).

## Supplementary figure 1

### A. Differential expression analysis




### B. Correlation and intersection with Microcosm Database

	Number	%
Differentially expressed miRNAs	259	
Differentially expressed mRNAs	1071	
Number of total correlations	276318	100
Total negative correlations	63032	22,81
Total negative correlations, p<0,05	37130	13,43
Total negative correlations, FDR<0,05	24031	8,70
Total targets predicted in MicroCosm	8463	100
Total negative correlated targets	1899	22,44
Total negative correlated targets, p<0,05	1137	13,43
Total negative correlated targets, FDR<0,05	775	9,16

## Supplementary Figure 2

A.



B.

